



Celgene Corporation  
Investor Relations Department  
86 Morris Avenue  
Summit, NJ 07901  
United States

[Visit IR website](#)   
[Sign-up for e-mail alerts](#)

#### NASDAQ: CELG

Last Trade:	95.26
Trade Time:	4:15 PM ET Feb 16, 2018
Change:	-0.88 (0.915%)
Day Range	95.24 - 96.80
52-Week Range	88.32 - 147.17
Volume	5,783,343

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID®, VIDAZA®, THALOMID®, POMALYST®/IMNOVID®, ABRAXANE®, OTEZLA®, ISTODAX® and IDHIFA®. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These cand... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Feb 17, 2018*  
[OTEZLA® \(Apremilast\) Phase III Data Showed Significant Improvements in Patients with Active Behçet's Disease with Oral Ulcers](#)

*Feb 15, 2018*  
[OTEZLA® \(Apremilast\) Phase II Data Showed Clinically Meaningful Improvements in Patients with Active Ulcerative Colitis](#)

*Feb 15, 2018*  
[Celgene Corporation Elects John Weiland to Its Board of Directors](#)

*Feb 14, 2018*  
[Celgene Announces Additional \\$5 Billion Share Repurchase Authorization](#)

*Feb 9, 2018*  
[Celgene Prices \\$4.5 Billion of Senior Unsecured Notes](#)

## Upcoming Events [\[ View all \]](#)

*Feb 21, 2018 11:30 AM ET*  
[RBC Capital Markets 2018 Global Healthcare Conferenc](#)

## Events [\[ View all \]](#)

## Financials [\[ View all \]](#)

*Feb 7, 2018*  
[Annual Report \(10-K\)](#)

*Apr 27, 2017*  
[Proxy Statement \(DEF 14A\)](#)

*Oct 26, 2017*  
[Quarterly Report \(10-Q\)](#)

*Jul 27, 2017*  
[Quarterly Report \(10-Q\)](#)

*Apr 27, 2017*  
[Quarterly Report \(10-Q\)](#)